Docetaxel

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg

Disponible desde:

REX Medical Ltd

Designación común internacional (DCI):

Docetaxel trihydrate 100.71 mg (equivalent to anhydrous docetaxel 80 mg)

Dosis:

80 mg/mL

formulario farmacéutico:

Concentrate for infusion

Composición:

Active: Docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Unidades en paquete:

Vial, glass, Diluent, 6 mL

clase:

Prescription

tipo de receta:

Prescription

Fabricado por:

Cipla Ltd

indicaciones terapéuticas:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Resumen del producto:

Package - Contents - Shelf Life: Vial, glass, Diluent - 6 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 80 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Fecha de autorización:

2006-06-23